Check whether claims match experiments, exact reported results, and stated limitations.Know what the science actually supports before you trust the answer.
Press Enter ↵ to review paper
Explore by Goal
"If the brain were so simple we could understand it, we would be so simple we couldn't."
- Lyall Watson
Quick Explanation
Copied
Skeptical, evidence-weighted read of the review
The 2021 review argues that Hippo pathway dysregulation—especially increased YAP/TAZ activity—contributes to therapy resistance across multiple cancer types and that multiple pharmacological strategies aim to suppress Hippo/YAP/TAZ outputs (e.g., TEAD–YAP disruption; upstream pathway modulation; transcriptional co-factor targeting).
Main blind spot: as a narrative synthesis, it cannot establish causal universality; YAP/TAZ can be context-dependent (oncogenic vs tumor-suppressive), and many mechanistic claims are based on heterogeneous preclinical systems and retrospective correlations.
Long Explanation
Paper Review (critical, evidence-based): “The Hippo Signaling Pathway in Drug Resistance in Cancer”
Published: 16 Jan 2021
Study type: Narrative review (no new primary experiments)
1) Core claim (what the review is really saying)
Mechanistic throughline: Hippo-pathway deregulation—commonly resulting in increased nuclear YAP/TAZ activity and downstream transcription—can promote resistance to multiple classes of anticancer drugs.
3) Visual: which drugs/cancers the review links to Hippo components
Count method: I extracted only the pairings explicitly summarized in the review’s Table 1 text (drug ↔ cancer type) and counted distinct cancer types per drug. This is a coverage metric of the review, not an incidence estimate in nature.
Interpretation (skeptical): a higher bar means “more distinct cancer contexts were discussed,” not necessarily “stronger causal evidence.” The review itself also notes contradictory YAP roles and tissue context dependence.
4) Hippo pathway biology (what is well-supported vs “reviewed as plausible”)
4.1 Canonical Hippo logic (upstream inhibition of YAP/TAZ)
The review summarizes the conserved kinase cascade where activated MST1/2–SAV1 phosphorylates and activates LATS1/2–MOB1, leading to YAP/TAZ phosphorylation, cytoplasmic retention, and degradation; unphosphorylated YAP/TAZ can enter the nucleus and partner with TEAD factors to drive gene expression programs tied to proliferation and survival.
Independent background: YAP/TAZ and TEAD are widely discussed as central drivers in cancer biology, and the literature documents both oncogenic and context-dependent tumor-suppressive roles.
Critique: Canonical Hippo-to-YAP/TAZ wiring is reasonably stable, but drug-resistance conclusions require which outputs (specific target genes, efflux transporters, anti-apoptotic factors, stemness programs) and which regulatory branch are causal in each cancer.
4.2 YAP/TAZ as drug-resistance mediators: what evidence type is typically implied
The review lists many drug classes and claims that Hippo/YAP/TAZ dysregulation can confer resistance, while inhibition or depletion can restore sensitivity in multiple preclinical contexts.
It also explicitly flags contradictory biology—e.g., YAP can exhibit tumor-suppressive roles in some contexts and its function may depend on p53-family status.
5) Visual: “targetability map” of Hippo-intervention concepts in the review
This chart groups intervention concepts listed in the review’s targeting sections and Table 2 (e.g., verteporfin; dobutamine; forskolin/PDE inhibitors; statins/mevalonate; Super-TDU; tyrosine kinase inhibitors; CDK9/BET inhibitors).
Critique: “Targetability” ≠ “clinical effectiveness.” Many compounds are supported by in vitro/in vivo preclinical findings summarized by the review; translational uncertainty is high, especially for YAP/TAZ inhibitors because YAP/TAZ can have context-dependent tumor-suppressive effects.
6) Skeptical evaluation: what is strong, what is weak, and what could mislead
Strengths (based on the review text itself)
Structured pathway grounding: the review clearly summarizes the Hippo kinase cascade and YAP/TAZ regulation logic, enabling readers to follow how upstream perturbations could change transcriptional outcomes.
Explicit acknowledgment of contradictions: it reports that YAP can be oncogenic or tumor-suppressive depending on context and highlights a proposed p53-family switch.
Weaknesses / likely blind spots (as a narrative review)
Selection bias & narrative bias: because the article is a synthesis of diverse studies, the review can overrepresent mechanisms that are repeatedly reported in the literature and underrepresent null/negative results. (This is an intrinsic methodological limitation of narrative reviews, not something we can quantify from the provided text.)
Context dependence is under-specified: the review notes contradictory YAP roles but does not provide a unified decision framework for when YAP/TAZ activity causally drives resistance versus when it correlates with other phenotypes.
Translational uncertainty: even if YAP/TAZ inhibition restores drug sensitivity in model systems, clinical effectiveness depends on biomarkers, tumor heterogeneity, and safety in tissues where Hippo/YAP/TAZ are important for homeostasis.
What would most likely disprove the review’s overarching narrative?
Demonstrating that YAP/TAZ inhibition (or upstream Hippo activation) does not restore sensitivity in well-controlled, biomarker-defined models across diverse genetic backgrounds and drug mechanisms—especially where the review claims broad relevance.
Showing that apparent “resistance links” are driven primarily by parallel pathways and that Hippo/YAP/TAZ changes are downstream markers rather than causal drivers. (The review itself highlights many cross-talk examples, but causal direction often remains unresolved in narrative synthesis.)
7) Bottom line (with confidence framing)
Most defensible takeaway
The review is strong as an organizing map: it ties canonical Hippo→YAP/TAZ control logic to a wide range of anticancer-drug resistance phenotypes and describes multiple intervention entry points that aim to reduce YAP/TAZ output.
Confidence note: the review’s directionality (“YAP/TAZ drives resistance” and “inhibiting YAP/TAZ re-sensitizes”) is plausible and repeatedly supported in cited preclinical literature, but because this is narrative synthesis, the overall claims should be treated as hypothesis-level until validated by systematic, biomarker-stratified clinical work.
Author reviews (open follow-ups)
Feedback:
Updated: March 23, 2026
BGPT Paper Review
Study Novelty
60%
The paper is a 2021 narrative synthesis of already-established Hippo/YAP/TAZ biology and drug-resistance themes; its novelty is primarily in breadth/organization rather than introducing new mechanistic paradigms.
Scientific Quality
70%
Scientific quality is moderate-to-strong for a narrative review: it provides a coherent pathway framework, and it explicitly flags context-dependent YAP roles and translation caveats. However, as a narrative synthesis it does not provide a systematic search strategy or quantitative evidence-weighting, limiting rigor against selective-citation and context-misalignment risks.
Study Generality
80%
It is broadly general across many cancer drug classes and cancer types, offering a cross-cancer map of Hippo/YAP/TAZ-associated resistance themes (while still being constrained by narrative synthesis).
Study Usefulness
80%
High utility as an entry-point for understanding where Hippo/YAP/TAZ intersects drug resistance and for generating hypotheses about mechanistic branches and candidate target nodes (e.g., upstream Hippo activation, YAP–TEAD disruption, transcriptional machinery).
Study Reproducibility
60%
Reproducibility is limited because the paper is a narrative review without a formal, reproducible systematic-review protocol, and it does not report original datasets or methods for quantitative meta-analysis.
Explanatory Depth
70%
It offers mechanistic depth at the pathway level and describes multiple resistance-associated mechanisms and intervention mechanisms, but it cannot resolve causal direction and tissue-specific determinants across all contexts because it aggregates heterogeneous primary studies.
Extract the review’s Table 1 pairings (drug→cancer types) and Table 2 intervention concepts, then auto-generate coverage plots and a directed citation graph from the included DOIs.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“YAP is always an oncogene and always drives resistance.” This fails because the review explicitly documents tumor-suppressive YAP behavior in some settings and proposes p53-family status as a switching determinant.
“Upstream Hippo activation alone will overcome resistance in all cancers.” This is undermined by the review’s repeated emphasis on context-dependent mechanisms, crosstalk, and incomplete understanding of downstream gene networks that more directly execute resistance.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion